Sabby Management’s Zevra Therapeutics ZVRA Stock Holding History

Sabby Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-70,000	Closed	-$321K	–	125
2022 Q4	$321K	Sell	70,000 -178,592	-72%	-$907K	0.28%	33
2022 Q3	$1.55M	Sell	248,592 -45,895	-16%	-$260K	1.96%	12
2022 Q2	$1.31M	Buy	294,487 +35,707	+14%	+$163K	0.89%	19
2022 Q1	$1.3M	Buy	258,780 +238,780	+1,194%	+$1.52M	0.19%	35
2021 Q4	$174K	Sell	20,000 -21,531	-52%	-$192K	0.03%	141
2021 Q3	$387K	Sell	41,531 -130,632	-76%	-$1.32M	0.05%	123
2021 Q2	$2.21M	Buy	+172,163	New	+$1.85M	0.31%	52

Other funds holding ZVRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Sabby Management's ZVRA Position: Q1 2023 in Review

Sabby Management sold out of Zevra Therapeutics (ZVRA) in Q1 2023, closing a stake of 70,000 shares — an estimated $321K sold.

Sabby Management first reported a position in ZVRA in Q2 2021 and held it in 7 quarters. The position peaked at $2.21M in Q2 2021. 60 funds tracked by Wall St. Rank hold ZVRA as of Q1 2023.

Sabby Management reported no remaining Zevra Therapeutics position as of Q1 2023 after selling out during the quarter.
Sabby Management sold 70,000 Zevra Therapeutics shares in Q1 2023, an estimated $321K.
Sabby Management first reported a position in Zevra Therapeutics in Q2 2021 and held it in 7 quarters.
Sabby Management's Zevra Therapeutics position peaked at $2.21M in Q2 2021.
60 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2023.

Based on Sabby Management's 13F filing for Q1 2023, filed 15 May 2023.